Usefulness of immunohistochemistry for the detection of the BRAF V600E mutation in ovarian serous borderline tumors

被引:7
作者
Hayashi, Yuko [1 ]
Sasaki, Hidefumi [2 ]
Takeshita, Sho [1 ]
Nishikawa, Ryutaro [4 ]
Nishikawa, Hiroshi [1 ]
Arakawa, Atsushi [1 ]
Yamashita, Yoriko [3 ]
Takahashi, Satoru [3 ]
Sugiura-Ogasawara, Mayumi [1 ]
机构
[1] Nagoya City Univ, Grad Sch Med Sci, Dept Obstet & Gynecol, Nagoya, Aichi 4678601, Japan
[2] Nagoya City Univ, Grad Sch Med Sci, Dept Oncol Immunol & Surg, Nagoya, Aichi 4678601, Japan
[3] Nagoya City Univ, Grad Sch Med Sci, Dept Pathol & Tumor Biol, Nagoya, Aichi 4678601, Japan
[4] Nagoya City East Med Ctr, Dept Obstet & Gynecol, Nagoya, Aichi 4648547, Japan
基金
日本学术振兴会;
关键词
BRAF mutation; immunohistochemistry; V600E expression; serous borderline tumor; ovary; CAST-PCR; LUNG ADENOCARCINOMA; KRAS; CARCINOMA; CANCER; PCR; PERITONEUM; SAMPLES; EGFR;
D O I
10.3892/or.2014.3442
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Serous borderline tumors and low-grade serous adenocarcinomas typically exhibit a low mitotic index and are largely resistant to chemotherapy. They are characterized by specific mutations, including mutations of KRAS and BRAF, which target specific cell signaling pathways. Mutational analyses may provide further insight into the development sequence of low-grade serous carcinomas. There are 3 methods to detect BRAF mutations: direct sequencing, such as Sanger sequencing (Sas); immunohistochemistry (IHC); and competitive allele-specific hydrolysis probe (TaqMan) PCR technology (CAST-PCR). In the present study, we matched the results of these 3 methods in ovarian serous borderline tumor cases. This study was carried out in 11 surgically removed ovarian serous borderline tumors. Detection of the BRAF V600E mutation was carried out by the FLEX detection system using the VE1 clone antibody and the results were compared with those of Sas and CAST-PCR. The autostainer IHC VE1 assay was positive in 3 of the 11 ovarian serous borderline tumors and negative in the remaining 8 tumors. CAST-PCR demonstrated a BRAF V600E mutation ratio of 16.4, 17.7 and 12.7%, respectively, in the 3 IHC-positive cases. Sas detected the BRAF V600E mutation in only 2 cases, while revealing wild-type BRAF in the remaining 9 cases. Sas revealed KRAS mutations in 2 of these 9 cases with wild-type BRAF. Our data suggest a high concordance rate of the results between CAST-PCR and IHC. Thus, IHC using the VE1 clone and FLEX linker is a specific method for the detection of BRAF V600E and may be an alternative to molecular-biologic techniques for the detection of mutations in ovarian serous borderline tumors. This method may be a useful screening method for the BRAF mutation.
引用
收藏
页码:1815 / 1819
页数:5
相关论文
共 50 条
[31]   Detection of the BRAF V600E Mutation in Colon Carcinoma Critical Evaluation of the Imunohistochemical Approach [J].
Lasota, Jerzy ;
Kowalik, Artur ;
Wasag, Bartosz ;
Wang, Zeng-Feng ;
Felisiak-Golabek, Anna ;
Coates, Tiffany ;
Kopczynski, Janusz ;
Gozdz, Stanislaw ;
Miettinen, Markku .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2014, 38 (09) :1235-1241
[32]   BRAF V600E Mutations in Endometrial Adenocarcinoma [J].
He, Mai ;
Breese, Virginia ;
Hang, Steven ;
Zhang, Cunxian ;
Xiong, Jinjun ;
Jackson, Cynthia .
DIAGNOSTIC MOLECULAR PATHOLOGY, 2013, 22 (01) :35-40
[33]   Immunohistochemical Examination is Highly Sensitive and Specific for Detection of the V600E BRAF Mutation in Colorectal Serrated Lesions [J].
Yamada, Noriyuki ;
Eizuka, Makoto ;
Sugimoto, Ryo ;
Tanaka, Yoshihito ;
Yanagawa, Naoki ;
Yamano, Hiroo ;
Suzuki, Hiromu ;
Matsumoto, Takayuki ;
Sugai, Tamotsu .
APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY, 2021, 29 (06) :446-453
[34]   Immunohistochemical analysis of BRAF V600E mutation in ameloblastomas [J].
Alan Motta do Canto ;
Barbara Michaela Reis da Silva Marcelino ;
Juliana Lucena Schussel ;
Bruna F. Wastner ;
Laurindo Moacir Sassi ;
Luciana Corrêa ;
Ronaldo Rodrigues de Freitas ;
Bengt Hasséus ;
Göran Kjeller ;
Celso Augusto Lemos Junior ;
Paulo Henrique Braz-Silva .
Clinical Oral Investigations, 2019, 23 :779-784
[35]   Immunohistochemical analysis of BRAF V600E mutation in ameloblastomas [J].
do Canto, Alan Motta ;
Reis da Silva Marcelino, Barbara Michaela ;
Schussel, Juliana Lucena ;
Wastner, Bruna F. ;
Sassi, Laurindo Moacir ;
Correa, Luciana ;
de Freitas, Ronaldo Rodrigues ;
Hasseus, Bengt ;
Kjeller, Goran ;
Lemos Junior, Celso Augusto ;
Braz-Silva, Paulo Henrique .
CLINICAL ORAL INVESTIGATIONS, 2019, 23 (02) :779-784
[36]   Presence of BRAF V600E Mutation in Nevus Cases [J].
Cetin, Aysen ;
Coban, Sermin ;
Demirkan, Nese Calli ;
Tufan, N. Lale Satiroglu ;
Tufan, A. Cevik ;
Bagci, Hueseyin .
TURKIYE KLINIKLERI TIP BILIMLERI DERGISI, 2010, 30 (02) :494-501
[37]   BRAF V600E mutation in thyroid nodules in Argentina [J].
Ilera, Veronica ;
Dourisboure, Ricardo ;
Colobraro, Antonio ;
Silva Croome, Maria Del Carmen ;
Olstein, Gustavo ;
Gauna, Alicia .
MEDICINA-BUENOS AIRES, 2016, 76 (04) :223-229
[38]   Immunohistochemistry is highly sensitive and specific for detecting the BRAF V600E mutation in papillary thyroid carcinoma [J].
Sun, Jian ;
Zhang, Jing ;
Lu, Junliang ;
Gao, Jie ;
Lu, Tao ;
Ren, Xinyu ;
Duan, Huanli ;
Liang, Zhiyong .
INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2015, 8 (11) :15072-15078
[39]   The use of BRAF V600E mutation-specific immunohistochemistry in pediatric Langerhans cell histiocytosis [J].
Ballester, Leomar Y. ;
Cantu, Miguel D. ;
Lim, Karen P. H. ;
Sarabia, Stephen F. ;
Ferguson, Lizmery Suarez ;
Webb, C. Renee ;
Allen, Carl E. ;
McClain, Kenneth L. ;
Mohila, Carrie A. ;
Punia, Jyotinder N. ;
Roy, Angshumoy ;
Lopez-Terrada, Dolores H. ;
Hicks, M. John ;
Fisher, Kevin E. .
HEMATOLOGICAL ONCOLOGY, 2018, 36 (01) :307-315
[40]   VE1 immunohistochemistry predicts BRAF V600E mutation status and clinical outcome in colorectal cancer [J].
Schafroth, Christian ;
Galvan, Jose A. ;
Centeno, Irene ;
Koelzer, Viktor H. ;
Dawson, Heather E. ;
Sokol, Lena ;
Rieger, Gregor ;
Berger, Martin D. ;
Haedrich, Marion ;
Rosenberg, Robert ;
Nitsche, Ulrich ;
Schnueriger, Beat ;
Langer, Rupert ;
Inderbitzin, Daniel ;
Lugli, Alessandro ;
Zlobec, Inti .
ONCOTARGET, 2015, 6 (39) :41453-41463